// App-Quantinova.ai

: Apabetalone (RVX-208) impacts key biomarkers and pathways associated with cardiovascular disease in patients with severe renal impairment

Researchers

Presenter

  • N. Wong

Principal Investigators

  • R. Robson

Medical Centers

  • Resverlogix Corp., Calgary, Canada

  • Christchurch Clinical Studies Trust, Christchurch, New Zealand

Locations

  • Canada

  • New Zealand

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • RVX-208

Outcome

  • N/A

Study Design

  • Pharmacokinetics

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved